erythromycin-sulfisoxazole (1/64) was more active than erythromycin alone but essentially equivalent in activity to sulfisoxazole alone. Finally, small numbers of clinical isolates of H. influenzae were resistant to trimethoprim-sulfamethoxazole and rifampin.
Antimicrobial resistance among clinical isolates of Haemophilus influenzae has become an increasingly prevalent problem (G. V. Doern, Antimicrob. Newsl. 5:28-34, 1986 ). In a national collaborative study conducted in 1984, 15 .2% of a large number of strains of H. influenzae produced Ilactamase (6) . The problem of ampicillin resistance is complicated by recent descriptions of clinical isolates of H. influenzae that are resistant to ampicillin by mechanisms other than the production of a TEM-type P-lactamase (10, 11, 14) . In addition, chloramphenicol resistance has now been reported (2, 15) , as has resistance to a variety of alternative agents commonly used to treat Haemophilus infections (Doern, Antimicrob. Newsl. 5:28-34). The intent of this investigation was to define systematically the prevalence of antimicrobial resistance among clinical isolates of H. influenzae in the United States. Rates of P-lactamase production and the activities of 12 antimicrobial agents were assessed. These agents included ampicillin, chloramphenicol, cefamandole, cefaclor, cephalothin, cephalexin, tetracycline, rifampin, erythromycin, sulfisoxazole, and the combinations erythromycin-sulfisoxazole and trimethoprim-sulfamethoxazole (TMP-SMX).
MATERIALS AND METHODS
Study centers. A total of 30 hospital-based microbiology laboratories and 1 national, private, independent laboratory participated in the study (Table 1) .
Clinical isolates. A total of 2,811 clinical isolates of H. influenzae were obtained as part of this investigation in 1986 * Corresponding author.
by the laboratories listed in Table 1 . All isolates were recovered from different patients and were randomly selected for inclusion in the study. After being characterized in study center laboratories, isolates were subcultured to chocolate agar slants (GIBCO Diagnostics, Madison, Wis.), which were incubated overnight in a CO2 atmosphere and then mailed, with selected patient demographic information, to one of two coordinating study centers for further characterization. The coordinating study centers were the Department of Clinical Microbiology, University of Massachusetts Medical Center, Worcester, and the Department of Pathology, University of Texas Health Science Center, San Antonio. Upon receipt in the coordinating study centers, growth from slants was transferred into 10% sterile skim milk and frozen at -70°C in 1-dram (ca. 3.7-ml) plastic freezer vials.
Isolate characterization. Frozen stock suspensions were thawed, and aliquots were subcultured to chocolate agar plates (GIBCO) which were incubated overnight at 35°C in 5 to 7% CO2. Individual isolated colonies were then subcultured to a second chocolate agar plate which was incubated under identical conditions. Growth from the second plate was used for the following analyses. Organisms were identified as H. influenzae on the basis of the following characteristics: typical colony and Gram stain morphology (8) , catalase production (7) , hemin dependence on the basis of the porphyrin test (8) ically for evidence of growth. An MIC was defined as the produced ,B-lactamase ( Table 1 ). The overall prevalence of lowest concentration of antimicrobial agent tested which t-lactamase production among the 2,811 study isolates was inhibited growth. A strain of H. influenzae for which the thus 20.0%. In general, whether isolates were categorized by MICs of the antimicrobial agents are known was used as a study center (Table 1) , patient age (Table 2) , or specimen daily control.
source (Table 3) , type b strains were more likely to produce P-lactamase than were non-type b strains.
RESULTS
The in vitro activities of five beta-lactam antimicrobial agents against the 2,811 study isolates are shown in Table 4 the basis of the NCCLS definition of susceptibility to TMPFrom the 2,797 isolates for which chloramphenicol MICs SMX, i.e., MICs of c0.5/9.5 ,ug/ml (Table 5 ) (13) . Of these were c4.0 ,ug/ml, 50 strains were selected for the assessment 25 strains, 17 (2 type b and 15 non-type b strains) were also of chloramphenicol acetyltransferase production. These in-P-lactamase positive. For 3 isolates (all 3-lactamase produccluded 3 strains for which the MIC was 4.0 jig/ml, 1 strain for ing and non-type b) among the 25 strains that were not which the MIC was 2.0 ,ug/ml, 20 strains for which the MIC susceptible to TMP-SMX, chloramphenicol and tetracycline was 1.0 ,ug/ml, 20 strains for which the MIC was 0.5 ,uglml, MICs were .8.0 ,g/ml. For these three strains, the actual and 6 strains for which the MIC was 0.25 ,ug/ml. None TMP-SMX MICs were 2.0/38, 4.0/76, and 4.0/76 jig/ml. In produced chloramphenicol acetyltransferase. For 50 of 2,797 addition, for one 3-lactamase-negative, non-type b strain of isolates (1.8%) for which chloramphenicol MICs were s4.0 H. influenzae which was not susceptible to TMP-SMX, the ,g/ml, tetracycline MICs were .8.0 p,g/ml.
tetracycline MIC was 16 ,ug/ml. The strain was susceptible to A total of 2,747 study isolates (97.7% of the total) were chloramphenicol (MIC, 1.0 ,ug/ml).The TMP-SMX MIC for susceptible to tetracycline on the basis of the NCCLS this strain was 16/304 ,ug/ml. guideline, i.e., MICs of c4.0 ,ug/ml (Table 5) 
(13). Of 64
Finally, for9 of 2,811 study isolates (0.7%), rifampin MICs strains for which tetracycline MICs were .8.0 ,ug/ml (20 were .4 ,ug/ml; thus, these 9 strains were not susceptible to VOL. 32, 1988 this agent on the basis of the NCCLS criterion (Table 5 ) (13) . All nine strains were non-type b, ,-lactamase negative, and susceptible to ampicillin, chloramphenicol, tetracycline, and TMP-SMX.
DISCUSSION
The results of this investigation suggest that the prevalence of 3-lactamase-mediated ampicillin resistance among clinical isolates of H. influenzae is increasing in the United States. In a nationwide surveillance study conducted in 1984, 21.0% of 1,156 type b strains and 12.1% of 2,200 non-type b strains produced 1-lactamase (6) . The present investigation with isolates obtained in 1986 showed that 31.7% of 757 type b strains and 15.6% of 2,054 non-type b strains were P-lactamase positive. Two observations made in the 1984 study were corroborated by the results of the present investigation. First, the overall rates of j-lactamase production were highest among H. influenzae isolates from patients in certain age groups (i.e., <5 years of age) and among isolates from specimens representative of systemic Haemophilus infections (i.e., blood and cerebrospinal fluid). This observation was largely a result of the greater numbers of type b strains recovered from younger patients and from systemic sites. Second, it was not possible to predict with certainty the prevalence of P-lactamase-positive H. influenzae for a given geographic area, because of the absence of any observed geographic clustering of ,-lactamase-producing strains. As a result, predictions of rates of P-lactamase production must be based on the experiences of individual medical centers.
It is very likely that the P-lactamase-positive strains of H. influenzae recovered in the present investigation produced a TEM-1-type P-lactamase. This assumption is based on two observations. First, the vast majority of 3-lactamase-producing strains of H. influenzae possess this enzyme (Doem, Antimicrob. Newsl. 5:28-34). Second, the nitrocefin disk test used to detect P-lactamase activity in the present study does not yield positive results with strains that possess the ROB-type P-lactamase (10) , the only other 1-lactamase described for H. influenzae.
If this is true, it appears that high-level ampicillin resistance among H. influenzae strains that lack the TEM-type 1-lactamase is extremely uncommon in the United States.
For only 2 isolates (both non-type b) from among 2,250 P-lactamase-negative strains characterized in this study were ampicillin MICs .16 ,ug/ml. In addition, for four 3-lactamase-negative isolates (all non-type b), ampicillin MICs were 4.0 pug/ml, and thus the isolates would be considered resistant on the basis of the criteria of the NCCLS (13) . Of interest, however, is the observation that for 65 isolates which lacked ,-lactamase, the ampicillin MIC was 2.0 ,ug/ml. These isolates might be considered moderately susceptible or even resistant to ampicillin despite the recommendations of the NCCLS (13), which suggests that H. influenzae strains for which ampicillin MICs are <2.0 ,ug/ml be considered susceptible (4). We base this assertion on the observation that for 17 ,-lactamase-positive strains in the present study, the ampicillin MIC was 2.0 ,ug/ml. If H. influenzae strains for which ampicillin MICs are .2.0 ,ug/ml were considered resistant, then the overall rate of ampicillin resistance among ,B-lactamase-negative isolates would be 3.2%. Four cephalosporin antimicrobial agents were examined.
Their activities against H. influenzae were in the following order: cefamandole > cefaclor . cephalothin > cephalexin.
Only 36 strains (1.3% of the total) were not susceptible to cefamandole. In contrast, 155 (5.5% of the total) and 358 (12.7% of the total) strains were not susceptible to cefaclor and cephalothin, respectively. Cephalexin had limited activity against H. influenzae. Isolates were considered susceptible to these four cephalosporins if MICs were s8.0 p,g/ml (13) . Cephalosporin activity did not seem to be influenced by P-lactamase activity, that is, the MICs of a given agent were similar for P-lactamase-positive and -negative strains.
Chloramphenicol resistance appears to be relatively uncommon in the United States. For 14 strains (0.5% of the total), chloramphenicol MICs were .8.0 p,g/ml, and thus these strains were considered resistant (5). All of these strains produced chloramphenicol acetyltransferase, and all were resistant to tetracycline. Two were type b strains; both produced ,B-lactamase. Of the 12 non-type b, chloramphenicol-resistant strains, 9 produced 1-lactamase.
Tetracycline was also highly active against most study isolates. Among all strains tested, 97.7% were determined to be susceptible to tetracycline based on the NCCLS-recommended MIC breakpoint of s4.0 ,ug/ml (13) . In contrast, both erythromycin and sulfisoxazole had limited activities against the H. influenzae strains examined in this investigation. Interestingly, erythromycin-sulfisoxazole, a combination frequently used to treat localized non-life-threatening Haemophilus infections in children, was considerably more active than erythromycin alone but equivalent in activity to sulfisoxazole alone. Clinical interpretation of MICs obtained with this combination, however, is difficult. For this investigation, a ratio of 1 part of erythromycin to 64 parts of sulfisoxazole was used to determine MICs (P. N. Whitley and S. I. Pelton, Program Abstr. 21st Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 11, 1981) . For these in vitro observations of inhibitory activity to have clinical relevance, a ratio of erythromycin to sulfisoxazole of approximately 1:64 would have to be achieved in vivo when this combination is used to treat Haemophilus infections. At least with respect to otitis media, the ratio of erythromycin to sulfisoxazole obtained in middle ear fluid appears to be much lower (9) .
While TMP-SMX was highly active against most study isolates, for 25 strains (0.9% of the total) MICs were -1.0/19 jig/ml, and thus these strains were not considered susceptible by NCCLS criteria (13) . Notable were 3 non-type b strains among these 25 that also demonstrated resistance to chloramphenicol and tetracycline, as well as 1-lactamasemediated ampicillin resistance. These strains seem similar to the multiply resistant strains of H. influenzae recently reported in Barcelona, Spain (3) . Finally, the results of the present investigation clearly documented the existence of at least small numbers of clinical isolates of H. influenzae with high-level resistance to rifampin.
In conclusion, the results of this extensive national surveillance study of antimicrobial resistance among clinical isolates of H. influenzae revealed the following. (i) The prevalence of ,B-lactamase-mediated ampicillin resistance continues to increase with both type b and non-type b strains.
The rate of P-lactamase-mediated ampicillin resistance among type b strains (i.e., 31.7%) indicates that the use of ampicillin alone for the empiric therapy of systemic Haemophilus infections is inappropriate. (ii) H. influenzae strains that are resistant to ampicillin by mechanisms other than the production of TEM-type P-lactamase are extremely uncommon. (iii) Chloramphenicol resistance is also unusual; however, when it occurs, it is invariably the result of chloramphenicol acetyltransferase production and is associated with P-lactamase production and tetracycline resistance. (iv) Resistance to TMP-SMX and rifampin, two antimicrobial agents previously considered nearly uniformly active against H. influenzae, was clearly documented. Fortunately, resistance to these agents remains uncommon; however, in the case of TMP-SMX it may co-occur with P-lactamase-mediated ampicillin resistance and resistance to chloramphenicol and tetracycline. (v) Cephalexin and erythromycin have no value in the treatment of infections caused by H. influenzae.
